Psoriasis: Recommendations for topical tacrolimus and pimecrolimus

  • Indications: 
    • No FDA-approved indications for psoriasis; primary indications for off-label use are for facial and intertriginous psoriasis.
  • Contraindications/adverse reactions:
    • There are no specific contraindications/adverse reactions for psoriasis.
    • Most common side effect for both medications is burning and itching.
    • A controversial lymphoma ‘‘black box’’ warning has been issued by the FDA.
Level of Evidence: II  Strength of Recommendation: B​

Navigate section 3 of the psoriasis guideline: Topical therapies

Citation note

When referencing this guideline in a publication, please use the following citation: Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM, Gordon KB,et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. J Am Acad Dermatol. 2009 Apr;60(4):643-59.